NCT06548347View on ClinicalTrials.gov

A Phase II/III Study of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell Lymphoma

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

606

Participants

Timeline

Start Date

September 10, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

September 30, 2029

Conditions

Peripheral T Cell Lymphoma

Interventions

DRUG

Linperlisib

Linperlisib at 80 mg orally once daily (QD) or 60mg orally once daily (QD) plus CHOP, placebo at 80mg or 60 mg orally once daily (QD) plus CHOP for 6 cycles

All Listed Sponsors

lead

Shanghai YingLi Pharmaceutical Co. Ltd.

INDUSTRY

NCT06548347 - A Phase II/III Study of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell Lymphoma | Biotech Hunter | Biotech Hunter